The quarter ended with sales exceeding MNOK 200 for the first time. Total sales
ended at MNOK 201.7 (MNOK 181.5), 11.1 % above Q1-2025.
Currency neutral sales of own products were up 28.8 % for the quarter. Strong
currency neutral growth in all geographies with APAC leading the way with 57.5 %
growth, AMERICAS grew by 30.9 %, while EMEA was up 11.5 %.
Third-party distributor sales in Scandinavia faced an exceptionally strong
comparable from Q1-2025 and decreased by 30.2 % for the quarter.
Operating profit (EBIT) ended at MNOK 57.1 for the quarter, resulting in 28.3 %
EBIT margin (MNOK 59.2, 32.6 % margin). Currency neutral EBIT was MNOK 61.4.
In February 2026, Medistim announced the establishment of a direct sales
operation in Japan, effective from March 16, 2026.
Recurring sales remained high at 67.8 % (67.7 %).
Solid cash position at quarter end with MNOK 209.8. The company has no
interest-bearing bank loans.
The General Assembly decided on a dividend of NOK 8.00 per share, total dividend
payment of MNOK 146.2.